StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) income statement

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$168.98−1.28 (-0.75%)

Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%

Gilead Sciences, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
79.9%
Operating margin
-7.6%
Net margin
-12.5%
Return on equity, FY2025
40.5%

Financial strength

Current ratio
1.38
Debt to equity
2.01
Debt to assets
51.0%
Cash to current liabilities
53.6%

Valuation

P/E ratio
–
Price to sales
6.76
Price to book
16.07
Dividend yield
1.87%

See a number that looks wrong?